"Nothing to lose and the possibility of gaining": a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians.
Oncology
Qualitative study
Registry-based randomised controlled trials
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
received:
14
04
2022
accepted:
20
01
2023
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
9
2
2023
Statut:
epublish
Résumé
Randomised controlled trials (RCTs) are considered the "gold standard" for evaluating the effectiveness of interventions in clinical research. However, conventional RCTs are typically complex, expensive, and have narrow eligibility criteria, which limits generalisability. Registry-based randomised controlled trials (RRCTs) are an alternative approach that integrates the internal validity of an RCT with the external validity of a clinical registry by recruiting real-world patients and leveraging an existing registry platform for data collection. As RRCT is a novel research design, there has been limited research on the feasibility and acceptability of RRCTs from the patients' and trial team's perspectives. This study aims to explore patients', clinicians', and study coordinators' perspectives towards participation in and conduct of oncology RRCTs in Australia. Thirty-seven semi-structured interviews were conducted with 15 cancer patients, 15 clinicians, and 7 study coordinators. Interviews were audio-recorded and transcribed verbatim. The data were analysed using thematic analysis. Three overarching themes were identified: (1) enablers and barriers to recruitment and enrolment of patients in RRCTs, (2) experiences of patients participating in RRCTs, and (3) recommendations for the implementation of future RRCTs. For patients, altruism and "trust in the clinician" were key reasons to participate in a RRCT. For clinicians and clinical trial coordinators, the RRCT study design was perceived as "simple and straightforward" but "less exciting" than RCTs. Competition from commercially sponsored RCTs poses challenges for investigator-led RRCTs recruitment, particularly if eligible patient numbers are low. There were limited impacts on patients' treatment experiences and clinicians' clinical workflow given that the RRCTs explored different standards of care. Recommendations to improve the enrolment of patients in RRCTs included generating greater buy-in from clinicians by increasing awareness of RRCTs via education initiatives and broader promotion of the "selling point" of RRCTs and providing monetary compensation to hospitals for enrolling patients. Whilst patients, clinicians, and study coordinators were generally supportive of RRCTs, several barriers to effective RRCT implementation in oncology were identified. Developing strategies to increase acceptance of the methodology by clinicians will help enhance the uptake of RRCTs in Australia and internationally.
Sections du résumé
BACKGROUND
BACKGROUND
Randomised controlled trials (RCTs) are considered the "gold standard" for evaluating the effectiveness of interventions in clinical research. However, conventional RCTs are typically complex, expensive, and have narrow eligibility criteria, which limits generalisability. Registry-based randomised controlled trials (RRCTs) are an alternative approach that integrates the internal validity of an RCT with the external validity of a clinical registry by recruiting real-world patients and leveraging an existing registry platform for data collection. As RRCT is a novel research design, there has been limited research on the feasibility and acceptability of RRCTs from the patients' and trial team's perspectives. This study aims to explore patients', clinicians', and study coordinators' perspectives towards participation in and conduct of oncology RRCTs in Australia.
METHODS
METHODS
Thirty-seven semi-structured interviews were conducted with 15 cancer patients, 15 clinicians, and 7 study coordinators. Interviews were audio-recorded and transcribed verbatim. The data were analysed using thematic analysis.
RESULTS
RESULTS
Three overarching themes were identified: (1) enablers and barriers to recruitment and enrolment of patients in RRCTs, (2) experiences of patients participating in RRCTs, and (3) recommendations for the implementation of future RRCTs. For patients, altruism and "trust in the clinician" were key reasons to participate in a RRCT. For clinicians and clinical trial coordinators, the RRCT study design was perceived as "simple and straightforward" but "less exciting" than RCTs. Competition from commercially sponsored RCTs poses challenges for investigator-led RRCTs recruitment, particularly if eligible patient numbers are low. There were limited impacts on patients' treatment experiences and clinicians' clinical workflow given that the RRCTs explored different standards of care. Recommendations to improve the enrolment of patients in RRCTs included generating greater buy-in from clinicians by increasing awareness of RRCTs via education initiatives and broader promotion of the "selling point" of RRCTs and providing monetary compensation to hospitals for enrolling patients.
CONCLUSIONS
CONCLUSIONS
Whilst patients, clinicians, and study coordinators were generally supportive of RRCTs, several barriers to effective RRCT implementation in oncology were identified. Developing strategies to increase acceptance of the methodology by clinicians will help enhance the uptake of RRCTs in Australia and internationally.
Identifiants
pubmed: 36747274
doi: 10.1186/s13063-023-07109-2
pii: 10.1186/s13063-023-07109-2
pmc: PMC9902247
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2023. The Author(s).
Références
J Surg Res. 2020 Nov;255:428-435
pubmed: 32619857
Trials. 2021 Nov 25;22(1):844
pubmed: 34823582
Am Heart J. 2010 Dec;160(6):1042-8
pubmed: 21146656
Asia Pac J Clin Oncol. 2019 Jun;15(3):188-189
pubmed: 30747499
J Clin Nurs. 2019 Jul;28(13-14):2443-2461
pubmed: 30673153
Br J Cancer. 2013 Apr 16;108(7):1402-7
pubmed: 23511558
Learn Health Syst. 2020 Jan 13;4(3):e10211
pubmed: 32685681
JACC Cardiovasc Interv. 2014 Aug;7(8):857-67
pubmed: 25147030
Trials. 2021 Sep 6;22(1):597
pubmed: 34488851
Eur J Endocrinol. 2021 Feb;184(2):R51-R59
pubmed: 33166271
Eur Urol. 2017 Nov;72(5):789-798
pubmed: 28578829
Asia Pac J Clin Oncol. 2022 Aug;18(4):344-352
pubmed: 34811922
BMC Geriatr. 2020 Jan 21;20(1):19
pubmed: 31964340
Diabetologia. 2022 Oct;65(10):1575-1586
pubmed: 35902386
Trials. 2018 Aug 4;19(1):419
pubmed: 30075741
Trials. 2020 Jun 22;21(1):552
pubmed: 32571382
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Cancer Control. 2018 Jan-Mar;25(1):1073274818765475
pubmed: 29592528
Asia Pac J Clin Oncol. 2018 Dec;14(6):365-373
pubmed: 29947051
J Clin Epidemiol. 2016 Dec;80:16-24
pubmed: 27555082
Acta Orthop. 2020 Oct;91(5):506-513
pubmed: 32567472
Nat Rev Cardiol. 2015 May;12(5):312-6
pubmed: 25781411
Br J Clin Pharmacol. 2018 Jun;84(6):1384-1388
pubmed: 29446851
Asia Pac J Clin Oncol. 2019 Jun;15(3):186-187
pubmed: 30747483